A. N. Snel

CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia

V. V. D. van der Velden, M. Jongen‐Lavrencic, T. Pabst, 2018, Leukemia.

Leukemic Stem Cell Frequency: A Strong Biomarker for Clinical Outcome in Acute Myeloid Leukemia

T. Pabst, G. Schuurhuis, G. Ossenkoppele, 2014, PloS one.

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

G. Schuurhuis, J. Janssen, G. Ossenkoppele, 2018, Journal of visualized experiments : JoVE.

Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting

P. Vyas, V. V. D. van der Velden, N. Khan, 2020, British journal of haematology.

Minimal residual disease detection defined as the malignant fraction of the total primitive stem cell compartment offers additional prognostic information in acute myeloid leukaemia

G. Schuurhuis, G. Ossenkoppele, A. A. van de Loosdrecht, 2012, International journal of laboratory hematology.

High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON/SAKK AML 42A study.

Bob Löwenberg, Carlos Graux, Nancy Boeckx, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.